INNOCARE - 2026 Self-examination report on insider trading of company stocks
INNOCARE - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We accept no liability for any loss caused by reliance on such content.
InnoCare Pharma Limited Nuocheng Jianhua Pharmaceutical Co., Ltd.
(Incorporated in the Cayman Islands with limited liability) (Stock code: 9969)
Overseas regulatory announcement
This announcement is made by InnoCheng Jianhua Pharmaceutical Co., Ltd. (the "Company") pursuant to the Securities and Exchange Commission of The Stock Exchange of Hong Kong Limited.
Made in accordance with Rule 13.10B of the Securities Listing Rules.
This is to set forth the "Announcement on Board Resolutions" and "About 2023" published by the Company on the website of the Shanghai Stock Exchange. The third vesting period of the initial grant portion of the Science and Technology Innovation Board restricted stock incentive plan and the second vesting period of the reserved grant portion Announcement on Compliance with vesting conditions during the vesting period", "Announcement on the invalidation of some restricted shares that have been granted but have not vested yet" "Announcement on the Use of Idle Own Funds for Cash Management", "Announcement on the Use of Idle Own Funds for Cash Management", "Announcement on the 2026 Science and Technology Innovation Self-examination report on the insider trading of the company's stocks under the restricted stock incentive plan, "2026
List of first grant incentive objects of the Science and Technology Innovation Board Restricted Stock Incentive Plan (as of the date of first grant)", "The Compensation Committee of the Board of Directors Regarding the Initial Grant of Part III of the 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan" Verification Opinions on the Vesting Period and the Vesting List of the Reserved Part for the Second Vesting Period", "Board of Directors Remuneration" The Committee’s verification of the list of first-time incentive recipients under the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan Opinions", "Shanghai Fangda Law Firm's Opinions on InnoCare Pharma Limited) 2025 Annual General Meeting of Shareholders”, “Shanghai Fangda Law Firm’s Legal Opinion on No.
InnoCare Pharma Limited 2023 Science and Technology Innovation Board Restricted Stock Incentive Plan The third vesting period of the planned initial grant part and the second vesting period of the reserved grant part vesting condition achievements and Legal Opinions on Matters Related to the Invalidation of Partial Restricted Stocks" and "Shanghai Fangda Law Firm's Legal Opinions on InnoCare Pharma Limited 2026 Science and Technology Innovation Board Restricted Stock Incentive "Legal Opinion on Matters Related to the First Grant of the Plan".
By order of the board of directors
Nuocheng Jianhua Pharmaceutical Co., Ltd. Chairman and Executive Director Dr. Cui Jisong
Hong Kong, June 16, 2026
As at the date of this announcement, the Board of Directors includes Dr. Cui Jisong, Chairman and Executive Director; Dr. Zhao Renbin, Executive Director; Non-executive Directors
Dr. Shi Yigong and Mr. Xie Ronggang; and independent non-executive directors Ms. Hu Lan, Dr. Dong Dandan and Professor Guan Kunliang.
A-share code: 688428 A-share abbreviation: Nuocheng Jianhua Announcement number: 2026-030 Hong Kong stock code: 09969 Hong Kong stock abbreviation: Nuocheng Jianhua
Nuocheng Jianhua Pharmaceutical Co., Ltd.
About the 2019 Science and Technology Innovation Board Restricted Stock Incentive Plan 2026 Self-examination report on insider trading of company stocks
The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.
or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.
InnoCheng Jianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held a directors' meeting on April 24, 2026 The meeting reviewed and approved the "2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (Draft) and its Summary" and other related
The proposal was disclosed on the Shanghai Stock Exchange website (www.sse.com.cn) on April 25, 2026.
Related announcements.
According to the "Administrative Measures for Equity Incentives of Listed Companies" (hereinafter referred to as the "Administrative Measures"), the "Administrative Measures for Equity Incentives of Listed Companies"
Shanghai Stock Exchange's Science and Technology Innovation Board Stock Listing Rules" and "Self-Regulatory Supervision Guidelines for Companies Listed on Science and Technology Innovation Board No. 4—— Equity Incentive Information Disclosure" and other laws, regulations and normative documents as well as the company's "Information Disclosure Management System"
In accordance with the relevant provisions of the "Insider Information Insider Registration and Management System", the company has passed the China Securities Depository and Clearing Co., Ltd.
The Shanghai Branch of the Responsible Company has implemented the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan").
Insider information of the "Incentive Plan") within 6 months before the public disclosure of the draft incentive plan (i.e. October 2025
From April 25 to April 24, 2026 (hereinafter referred to as the "self-examination period"), the company's stock purchases and sales were carried out. Self-examination, the details are as follows:
Scope and procedures of verification
The verification objects are the insiders of the incentive plan (hereinafter referred to as the "verification objects").
Insiders of the incentive plan filled in the "Insider Information Insider Registration Form".
The company reports to the Shanghai Branch of China Securities Depository and Clearing Co., Ltd. about the inspection objects during the self-inspection period.
The company's stock trading situation was inquired and confirmed by the China Securities Depository and Clearing Co., Ltd. Shanghai
The branch issued an inquiry certificate.
- Explanation on the purchase and sale of company stocks by the subject of verification
According to the "Shareholdings and Share Changes of Information Disclosure Obligors" issued by China Securities Depository and Clearing Co., Ltd.
"Change Inquiry Certificate" and "Shareholder Share Change Detailed List", during the self-examination period of the incentive plan, a total of 1 person verified
The subject has purchased and sold company stocks.
After verification, the company believes that the transaction changes of the above-mentioned person during the self-examination period were based on the company’s public disclosure. The information disclosed and the operation based on the independent judgment of the secondary market transactions, when buying and selling the company's stocks
Currently, we are not aware of the relevant information of this incentive plan, and no one has disclosed this incentive plan to us.
relevant information or recommend that they buy or sell the company's stocks based on this, and there is no use of inside information for stock trading.
situation. Except for the above persons, none of the other persons subject to the inspection bought or sold the company's stocks during the self-examination period.
behavior.
- Conclusion
In the process of planning the incentive plan, the company strictly follows the "Management Measures" and the company's "Information Disclosure"
Management System" and the relevant provisions of the "Insider Information Insider Registration Management System", strictly limiting participation in planning
The scope of persons discussed was recorded in a timely manner at relevant company personnel and intermediaries who had access to inside information. records and take appropriate confidentiality measures.
After verification, during the self-examination of the incentive plan, none of the insiders took advantage of the company's incentive plan.
Plan to conduct stock trading activities with relevant inside information or leak relevant inside information about incentive plans.
Announcement is hereby made.
Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.
June 17, 2026